Evidence map›Paper›PMID 40166912›Full record

ArticleMultiple sclerosis (Houndmills, Basingstoke, England)2025

Long-term acceptability of MSReactor digital cognitive monitoring among people living with multiple sclerosis.

Daniel Merlo, Johnson Ja, Yi Chao Foong, Chao Zhu, Melissa Gresle, Tomas Kalincik, Jeannette Lechner-Scott, Trevor Kilpatrick, Michael Barnett, Bruce Taylor and 4 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Multiple sclerosis (Houndmills, Basingstoke, England), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Review
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Daniel MerloDepartment of Neuroscience, School of Translational Medicine, Monash University, Melbourne, VIC, Australia.ORCID 0000-0001-8766-3453
Johnson JaDepartment of Neurology, Alfred Health, Melbourne, VIC, Australia.
Yi Chao FoongDepartment of Neuroscience, School of Translational Medicine, Monash University, Melbourne, VIC, Australia.ORCID 0000-0001-6447-078X
Chao ZhuDepartment of Neuroscience, School of Translational Medicine, Monash University, Melbourne, VIC, Australia.
Melissa GresleDepartment of Neuroscience, School of Translational Medicine, Monash University, Melbourne, VIC, Australia.
Tomas KalincikCORe, Department of Medicine, The University of Melbourne, Melbourne, VIC, Australia.ORCID 0000-0003-3778-1376
Jeannette Lechner-ScottSchool of Medicine and Public Health, The University of Newcastle, Newcastle, NSW, Australia.
Trevor KilpatrickNeuroimmunology Centre, Department of Neurology, The Royal Melbourne Hospital, Melbourne, VIC, Australia.
Michael BarnettBrain and Mind Centre, The University of Sydney, Sydney, NSW, Australia; Sydney Neuroimaging Analysis Centre, Sydney, NSW, Australia.ORCID 0000-0002-2156-8864
Bruce TaylorMultiple Sclerosis, Menzies Research Institute, University of Tasmania, Hobart, TAS, Australia.
Katherine BuzzardNeuroimmunology Centre, Department of Neurology, The Royal Melbourne Hospital, Melbourne, VIC, Australia.
David DarbyDepartment of Neuroscience, School of Translational Medicine, Monash University, Melbourne, VIC, Australia.
Helmut ButzkuevenDepartment of Neuroscience, School of Translational Medicine, Monash University, Melbourne, VIC, Australia.
Anneke van der WaltDepartment of Neuroscience, School of Translational Medicine, Monash University, Melbourne, VIC, Australia.ORCID 0000-0002-4278-7003

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundMonitoring of cognition in multiple sclerosis (MS) is critical. Traditional cognitive testing is resource intensive and insensitive to subtle changes. Digital tests could address this need; however, their long-term usability remains unexplored.

objectivesTo determine the long-term acceptability and feasibility of digital cognitive measures in MS.

methodsParticipants with relapsing or secondary progressive MS were prospectively enrolled. MSReactor, a web-based test evaluating processing speed, attention and working memory, was performed 6-monthly for up to 36 months. Patient acceptability, anxiety, depression and quality of life were collected concurrently. Correlations between test acceptability, psychosocial measures, physical disability and cognition were analysed using Spearman's correlation.

resultsThis study included participants with complete data at 12 (

conclusionLong-term cognitive monitoring was highly acceptable. We identified characteristics, such as increased anxiety, that were associated with reduced acceptability. Patients with these characteristics may benefit from support to maintain monitoring. These findings underscore the potential for integrating such tools into MS care.

Indexed as

Cognitive DysfunctionMultiple SclerosisMultiple Sclerosis, Chronic ProgressiveMultiple Sclerosis, Relapsing-RemittingNeuropsychological TestsPatient Acceptance of Health CareAdultAnxietyFeasibility StudiesFemaleHumansMaleMiddle AgedProspective StudiesQuality of Lifecognitiondigital biomarkersdigital outcomesMultiple sclerosisprocessing speed

Identifiers

PMID40166912
PMCPMC12008470

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.